Following Initial Sale, Keck Medicine of USC to Become First Ablatherm Robotic HIFU Reference and Training Center in the U.S.

LYON, France , Nov. 24, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced data from a multicenter trial demonstrating encouraging outcomes of focal HIFU as a new treatment strategy for patients with unilateral localized prostate cancer.

Obtained FDA clearance for Ablatherm® HIFU in November Received first four U.S. orders for Ablatherm Record nine-month net sales of €20.5 million HIFU treatment-driven revenue increased 41% year-over-year Strong backlog for both lithotripsy and HIFU divisions entering Q4 First Focal One® Device

Conference Call and Webcast Scheduled for 8:30 a.m. ET

First HIFU Devices to be Shipped to the U.S. Next Week

Deadline for Appeals Passes With no Notice of Appeal Filed

First Focal One(R) Device Sold in Latin America

LYON, France , Nov. 9, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Ablatherm® Integrated Imaging HIFU in the U.S.

Multiple abstracts on whole prostate gland and focal HIFU presented at World Congress of Endourology and Lithotripsy Two HIFU studies presented at Société Internationale d'Urologie Company highlights Technology as exhibiting sponsor at Five Major American Urological Association Section Meetings

Clearance of Predicate HIFU Technology for Ablation of Prostatic Tissue Permits Streamlined 510(k) Pathway